Gentian Diagnostics

TekBot · mai 5, 2023, 3:06pm

Mandatory notification of trade

Moss, 5 May 2023

Gentian Diagnostics ASA (“Gentian”) has today been notified that the following transaction has been completed by a close associate of a primary insider in Gentian:
…

Vis børsmeldingen

Holta Invest AS (“Holta”), a close associate of primary insider Espen Tidemann Jørgensen, board member, is in the process of simplifying its group structure. The re-organization will result in its ownership in Gentian, currently owned indirectly through Holta Life Sciences AS and Holta Horisont AS, will be owned directly by Holta. Holta’s total ownership in Gentian will remain unchanged as a result of the re-organization.

Firstly, Holta Horisont AS has today sold all its 13,800 shares in Gentian to Holta Invest AS at a share price of NOK 47.50 per share.

Secondly, Holta Life Sciences AS has today sold all its 1,214,702 shares in Gentian to Holta Invest AS at a share price of NOK 47.50 per share.

Following the above transactions Holta Horisont AS and Holta Life Sciences AS hold no shares in Gentian. Holta’s total ownership of 1,228,702 shares (7,97%) in Gentian has not changed as result of the above transactions.

IR Contact: Njaal Kind, Group CFO, njaal.kind@gentian.no, +47 91 90 65 25

Please refer to the attached notification of trading for further details. This information is subject to the disclosure requirements in the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Kilde

Do2Do · mai 5, 2023, 3:10pm

Transcript fra dagens Q-presentasjon
230505_Gent_Q12023_TRANSCRIPT.pdf (212,5 KB)

TekBot · mai 5, 2023, 3:26pm

Disclosure of shareholdings – Holta Invest AS

Moss, 5 May 2023

Holta Invest AS is in the process of simplifying its group structure whereby its ownership in Gentian Diagnostics ASA, previously owned indirectly through Holta Life Sciences AS (which is wholly owned by Holta Invest AS) and Holta Horisont AS (which is 85% owned by Holta Invest AS) now are owned directly by Holta Invest AS.
…

Vis børsmeldingen

The above re-organization has been completed by each of Holta Horisont AS and Holta Life Sciences AS on 5 May 2023 having sold all its 13,800 shares and 1,214,702 shares, respectively, in Gentian Diagnostics ASA to Holta Invest AS. Following the transaction from Holta Horisont AS and Holta Life Sciences AS to Holta Invest AS, Holta Invest AS holds 1,228,502 shares in Gentian, corresponding to approximately 7.97 per cent of the total shares and votes (based on 15,422,350 number of outstanding shares).

This disclosure is made pursuant to Section 4-2 of the Norwegian Securities Trading Act.

Kilde

TekBot · mai 8, 2023, 12:41pm

Reminder: Invitation to Capital Markets Day 10 May 2023

Gentian Diagnostics will host a capital markets day for investors, analysts and media on 10 May 2023 at the company’s headquarter in Bjørnåsveien 5, 1596 Moss, Norway. In-person attendance is encouraged. The presentations from the event will be broadcasted live to participants not able to join in person.

Programme for the day:
…

Vis børsmeldingen

12.00-12.30 CEST: Registration and light lunch

12.30-15.00 CEST: Presentations covering the following topics

Introduction – Hilja Ibert CEO

R&D review – Torsten Knuttel – VP R&D

From science to sales: Gentian’s successful journey for established products – Aleksandra Havelka CSO and Markus Jaquemar CCO

Strategic roadmap – Njaal Kind CFO

15.00-16.00 CEST: Site visit

Please register your attendance to the capital markets day using the following link: Form , or send an e-mail to invest@gentian.no

IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

Kilde

TekBot · mai 10, 2023, 8:43am

Capital Markets Day at 12.30 CEST today

TekBot · juni 15, 2023, 6:40am

Gentian acquires Getica for SEK 3.0 million

Moss, 15 June 2023

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, is pleased to announce that it has entered into an agreement to acquire Getica AB from Erling Sundrehagen. Getica AB, located in Gothenburg Sweden, is currently offering antibody purification services exclusively to Gentian Diagnostics and is also a provider of diagnostics research & development services. The company currently has five employees.
…

Vis børsmeldingen

With this acquisition, Gentian Diagnostics will secure critical production competence in an essential step in the manufacturing process and realize operational gains estimated to be approximately NOK 2.0 million from 2024. In addition, Gentian Diagnostics will gain access to unique R&D capabilities.

Under the agreement, Gentian Diagnostics will pay a cash consideration of SEK 3.0 million for Getica AB and closing is expected to take place in early July.

IR contact:

Njaal Kind, CFO and COO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

Kilde

TekBot · august 16, 2023, 7:34am

Invitation to presentation of second quarter results

Do2Do · august 24, 2023, 6:18am

GENT med vekst og positiv EBIT i Q2 - det er jo noe å ta med seg NewsWeb

De har jo spist av kassen hvert kvartal de siste årene, mulig vi kan nå begrave emisjonsspøkelset for en stund.

De beholder ambisjonen om 1 mrd NOK omsetning, men når det skal skje (5-7 år har de skrevet i flere år) er nå fjernet

Haltopen · august 24, 2023, 6:47am

Får håpe de klarer snu det til positive resultat heretter. Men ikke helt overbevist når organisk vekst kun er 2%.

up 13% vs 2Q22. Revenue of MNOK 65.6 in 1H23 up 30% vs 1H22. Organic growth for the quarter was 2% in 2Q23 vs 2Q22 and 17% in 1H23 vs 1H22

Andre positive elementer:

Increased use of Cystatin C recommended in updated guidelines for clinical use, of which the proposed update from KDIGO is the most recent one, resulting in further expansion of the global market*

Confirmed value, validated by clinical trial, of GCAL for early detection of severe infections and prediction of clinical deterioration in an emergency setting

Third Party product sales increased by 112% in Q2 and 68% for H1, driven by the new fCAL® turbo contracts in Sweden and Norway

Progress NT-proBNP ?

TekBot · august 29, 2023, 11:55am

Mandatory notification of trade

TekBot · september 29, 2023, 11:43am

Expanding product portfolio with turbidimetric Retinol-Binding Protein (RBP) immunoassay

Moss, 29 September 2023

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, is pleased to announce that its new CE-marked Gentian Retinol-Binding Protein Immunoassay is now available for sale. This diagnostic test is an insourced product from a reputable European supplier which has enabled Gentian to launch the product quickly and without significant R&D spend.
…

Vis børsmeldingen

The assay is instrument independent and can be applied on a wide range of automated clinical chemistry analysers with a normal process time of less than 10 minutes.

The company sees an increasing demand for this assay, largely driven by an aging population and lifestyle associated diseases and deficiencies. Further, the company estimates the market for RBP to EUR 10-20 million. The initial market focus will be on Europe, followed by the US, both by pursuing established distribution channels, but also through new partners.

The Gentian RBP assay contributes to the diagnosis and monitoring of population wide diseases. RBP is a transport protein for retinol (vitamin A) in blood, synthesised in the liver and reabsorbed in the kidney. The diagnostic value is to be found in altered levels of circulating RBP in many conditions, including: vitamin A deficiency, undernutrition, renal dysfunction and diabetes.

The global increase of chronic diseases, such as diabetes and kidney disease as well as high prevalence of malnutrition, underlines the importance of analysing RBP to shed further light on these conditions. Studies show that RBP levels are elevated in patients with diabetes and renal dysfunction and reduced in conditions such as vitamin A deficiency and undernutrition [1,2]. Malnutrition presents a substantial socioeconomic challenge in today’s healthcare landscape, especially in long-term care facilities, where the prevalence has been reported to be as high as 85% [3].

Gentian Diagnostics’ CEO Dr. Hilja Ibert says: “Today’s launch of the Gentian Retinol-Binding Protein Immunoassay is part of our ambition to bring a steady stream of high-impact diagnostic tests to market, using our expertise in moving immunoassays from low-volume to high-volume clinical analysers”.

For sales and marketing enquiries
Markus Jaquemar, CCO markus.jaquemar@gentian.com +47 919 21 709

For investor enquiries
Njaal Kind, CFO
Njaal.kind@gentian.com +47 919 06 525

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protect life. Gentian is based in Moss, Norway, serving the global and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.

References: 1. Tanumihardjo, S.A., et al., Biomarkers of Nutrition for Development (BOND)-Vitamin A Review. J Nutr, 2016. 146(9): p. 1816s-48s. 2. Steinhoff, J.S., A. Lass, and M. Schupp, Retinoid Homeostasis and Beyond: How Retinol Binding Protein 4 Contributes to Health and Disease. Nutrients, 2022. 14(6). 3. Bharadwaj, S., et al., Malnutrition: laboratory markers vs nutritional assessment. Gastroenterology Report, 4(4), 2016, 272–280

Kilde

TekBot · oktober 18, 2023, 10:21am

Invitation to presentation of third quarter results

TekBot · oktober 26, 2023, 6:01am

Third quarter 2023 report

Moss, 26 October 2023

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the third quarter of 2023.
…

Vis børsmeldingen

Highlights

• Sales of MNOK 32.1 in 3Q23, up 39% vs 3Q22 (29% organic growth). Revenue of MNOK 97.7 YTD 2023 up 33% (21% organic growth) vs YTD 2022.

• EBITDA of NOK 1.2 million in 3Q23 and NOK 4.3 million YTD 2023, compared to EBITDA of NOK -6.1 million in 3Q22 and NOK -11.5 million YTD 2022.

• Cystatin C sales increased 90% in 3Q23 compared to 3Q22 and 39% YTD 2023 vs YTD 2022.

• Launch of Gentian Retinol-Binding Protein (RBP) Immunoassay. A new CE-marked turbidimetric instrument independent assay, with the key demand driver being the aging population and lifestyle associated diseases and deficiencies.

Webcast

Gentian’s CEO Hilja Ibert and CFO Njaal Kind will present the results today at 10.00 am, followed by a Q&A session. Join the webcast and submit questions via the following link:

https://attendee.gotowebinar.com/register/7976233815452043612

The webcast will be available on the company website after the presentation.

IR contact:

Njaal Kind, CFO and COO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian Diagnostics ASA, on 26 October 2023 at 08:00 CET.

About Gentian
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.

Kilde

Haltopen · oktober 26, 2023, 6:25am

90% vekst for Cyst C, > 30 mnok omsetning i det historisk sett svakeste kvartalet.

Er dette starten på gjennombruddet ?

Savepig · oktober 26, 2023, 3:15pm

Får meg til å heve øyenbrynene ihvertfall

Inntektene økte for Gentian

09:18

Infront TDN Direkt / E24

DEL

Gentian Diagnostics fikk en omsetning på 35 millioner kroner i tredje kvartal 2023, mot en omsetning på 25 millioner kroner samme periode året før.

Det fremgår av kvartalsrapporten torsdag.

Selskapet fikk et driftsresultat på minus 1,2 millioner kroner i tredje kvartal 2023, mot minus 8,7 millioner kroner samme kvartal året før.

Resultatet før skatt endte på minus 0,8 millioner kroner.

Kontantbeholdningen til selskapet ved utgangen av kvartalet var 76,4 millioner kroner.

Haltopen · oktober 26, 2023, 3:35pm

Store bestillinger fra Asia bidrar til salgsvekst for Gentian Diagnostics

– Den underliggende veksten er i ferd med å gå tilbake til nivåene vi så før pandemien, som vi selvfølgelig setter pris på, sier Gentian-direktør HIlja Ibert.

https://medwatch.no/nyheter/medtek_lab/article16546744.ece

TekBot · november 24, 2023, 9:08am

Mandatory notification of trade

Moss, 24 November 2023

Reference is made to the annual general meeting 18 May 2022 where guidelines for remuneration of executive personnel were approved. In accordance with these guidelines the board of Gentian Diagnostics ASA has allocated a total of 339,962 options to key employees under the existing option program.
…

Vis børsmeldingen

The following number of options have been allocated to primary insiders of Gentian Diagnostics ASA:

Hilja Ibert, Chief Executive Officer: 139,962 options. Following the allocations Ms. Ibert holds 6,525 shares and 359,924 options.

Njaal Kind, Group Chief Financial Officer: 40,000 options. Following the allocations Mr. Kind holds 26,125 shares and 180,670 options in the Company.

Markus Jaquemar, Chief Commercial Officer: 40,000 options. Following the allocation Mr. Jaquemar holds 87,500 options in the Company.

Aleksandra Havelka, Chief Scientific Officer: 30,000 options. Following the allocation Ms. Havelka hold 2,000 shares and 70,000 options in the Company.

Torsten Knüttel, Vice President R&D: 30,000 options. Following the allocation Mr. Knüttel holds 1,125 shares and 70,000 options in the Company.

The exercise price for the options granted is NOK 40,71 being the being the average volume-weighted share price on the Oslo Stock Exchange for the past 10 trading days prior to 24 November 2023. The right to exercise the options is vested over a period of 2 years, with 50% of the options vesting by the end of each year as follows: (i) 50% of the options granted, no earlier than 3 years after the allocation date (ii) 50% of the options granted, no earlier than 4 years after the allocation date.

Attached are the notifications of the transactions pursuant to the market abuse regulation article 19.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

For further information, please contact:
Njaal Kind
CFO, Gentian Diagnostics ASA
E-mail: njaal.kind@gentian.no
Phone. +47 919 06 525

Kilde

TekBot · desember 11, 2023, 12:30pm

Financial calendar

TekBot · desember 14, 2023, 8:25am